Replies to post #2392 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>Didn't anyone find this blurb important, in the positive sense? "Efavirenz appeared to be active against IDX899 resistant viruses and IDX899 remained active against efavirenz-resistant virus containing as many as four NNRTI-resistance mutations."<

This is not a new revelation—JP has been saying it in IDIX’s recent investor presentations. It is consequential, however, and I thought that came through in my annotations at the top of the post. Perhaps I wasn’t sufficiently exuberant :-)